Biomere Indirect: A Revolution in Enzyme Replacement Therapy

We're based business of about two billion dollars we're now profitable we have big cash balances. We are in a position with those two drugs to double the revenues of the company by 2025 to you know around four billion dollars and then one other one I mentioned is called nps4. Our base business of enzyme replacement therapy is still growing after many many years about you know low single digits but it's still growingand uh it's pretty well protected from competition for many many years so so you have you have a You have a lot of downside protection with our base business and a potential significant upside with voxogo in econropeja and rotévin in hemophia.